サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1413111

ネオアンチゲンがんワクチン市場：製品,技術,デリバリーメカニズム,ネオアンチゲンタイプ,投与経路,用途別- 世界予測2024-2030年

Neoantigen Cancer Vaccine Market by Product, Technology, Delivery Mechanism, Neoantigen Type, Route of Administration, Application - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 190 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ネオアンチゲンがんワクチン市場：製品,技術,デリバリーメカニズム,ネオアンチゲンタイプ,投与経路,用途別- 世界予測2024-2030年
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 190 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ネオアンチゲンがんワクチン市場規模は2023年に5,714万米ドルと推定され、2024年には6,044万米ドルに達すると予測され、CAGR 5.17%で2030年には8,135万米ドルに達すると予測されます。

ネオアンチゲンがんワクチンの世界市場

主な市場の統計
基準年[2023］ 5,714万米ドル
予測年[2024] 6,044万米ドル
予測年［2030] 8,135万米ドル
CAGR（%） 5.17%
ネオアンチゲンがんワクチン Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはネオアンチゲンがんワクチン市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、ネオアンチゲンがんワクチン市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-ネオアンチゲンがんワクチン市場の市場規模および予測は？

2-ネオアンチゲンがんワクチン市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-ネオアンチゲンがんワクチン市場における技術動向と規制の枠組みは？

4-ネオアンチゲンがんワクチン市場における主要ベンダーの市場シェアは？

5-ネオアンチゲンがんワクチン市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界的にがんの有病率が上昇
      • ゲノム配列決定と免疫療法の改善
      • がんの早期診断と治療に対する傾向
    • 抑制要因
      • 製造コストが高く複雑
    • 機会
      • ネオアンチゲンがんワクチンの有効性を向上させるための継続的な研究開発
      • 併用療法の新たな開発
    • 課題
      • 副作用と倫理的問題
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 ネオアンチゲンがんワクチン市場：製品別

  • 市販のネオアンチゲンワクチン
  • 個別化ネオ抗原ワクチン

第7章 ネオアンチゲンがんワクチン市場：技術別

  • HLAのタイピング
  • RNAシーケンス
  • 全ゲノム配列決定

第8章 ネオアンチゲンがんワクチン市場配信メカニズム別

  • エレクトロポレーション
  • ジーン・ガン
  • リポソーム
  • ウイロソーム

第9章 ネオアンチゲンがんワクチン市場ネオアンチゲンの種類別

  • 樹状細胞
  • 核酸
  • 合成ロングペプチド
  • 腫瘍細胞

第10章 ネオアンチゲンがんワクチン市場：投与経路別

  • 筋肉内
  • 静脈内
  • 経皮

第11章 ネオアンチゲンがんワクチン市場：用途別

  • 脳腫瘍
  • 消化器がん
  • 肺がん
  • 黒色腫

第12章 南北アメリカのネオアンチゲンがんワクチン市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第13章 アジア太平洋地域のネオアンチゲンがんワクチン市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第14章 欧州・中東・アフリカのネオアンチゲンがんワクチン市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第15章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第16章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • "
    • "Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
    • Advaxis Inc.
    • Agenus Inc.
    • AstraZeneca plc
    • Avidea Technologies
    • BioLineRx
    • BioNTech SE
    • Brightpath Biotherapeutics Co., Ltd.
    • CureVac N.V.
    • Elicio Therapeutics Inc
    • F. Hoffmann-La Roche Ltd.
    • Genocea Biosciences Inc
    • Gilead Sciences, Inc.
    • Gritstone bio, Inc.
    • Immunomic Therapeutics, Inc.
    • IMV Inc
    • ISA Pharmaceuticals BV
    • Medigene AG
    • Merck & Co., Inc.
    • Neophore Limited
    • Nouscom
    • Nykode Therapeutics ASA
    • OSE Immunotherapeutics
    • Takis srl
  • 主要な製品ポートフォリオ

第17章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. NEOANTIGEN CANCER VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. NEOANTIGEN CANCER VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. NEOANTIGEN CANCER VACCINE MARKET DYNAMICS
  • FIGURE 7. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 10. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2023 VS 2030 (%)
  • FIGURE 12. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2023 VS 2030 (%)
  • FIGURE 14. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 16. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 18. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 22. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 27. NEOANTIGEN CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 28. NEOANTIGEN CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. NEOANTIGEN CANCER VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 6. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY OFF-THE SHELL NEOANTIGEN VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEO-ANTIGEN VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 9. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HLA TYPING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 13. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY GENE GUN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VIROSOMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NUCLEIC ACID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC LONG PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY BRAIN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY GASTROINTESTINAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 281. NEOANTIGEN CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 282. NEOANTIGEN CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 283. NEOANTIGEN CANCER VACCINE MARKET LICENSE & PRICING
目次
Product Code: MRR-5C6F41F5B004

[190 Pages Report] The Neoantigen Cancer Vaccine Market size was estimated at USD 57.14 million in 2023 and expected to reach USD 60.44 million in 2024, at a CAGR 5.17% to reach USD 81.35 million by 2030.

Global Neoantigen Cancer Vaccine Market

KEY MARKET STATISTICS
Base Year [2023] USD 57.14 million
Estimated Year [2024] USD 60.44 million
Forecast Year [2030] USD 81.35 million
CAGR (%) 5.17%
Neoantigen Cancer Vaccine Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Neoantigen Cancer Vaccine Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Neoantigen Cancer Vaccine Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Neoantigen Cancer Vaccine Market, highlighting leading vendors and their innovative profiles. These include ", "Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc., Advaxis Inc., Agenus Inc., AstraZeneca plc, Avidea Technologies, BioLineRx, BioNTech SE, Brightpath Biotherapeutics Co., Ltd., CureVac N.V., Elicio Therapeutics Inc, F. Hoffmann-La Roche Ltd., Genocea Biosciences Inc, Gilead Sciences, Inc., Gritstone bio, Inc., Immunomic Therapeutics, Inc., IMV Inc, ISA Pharmaceuticals BV, Medigene AG, Merck & Co., Inc., Neophore Limited, Nouscom, Nykode Therapeutics ASA, OSE Immunotherapeutics, and Takis srl.

Market Segmentation & Coverage

This research report categorizes the Neoantigen Cancer Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Off-The Shell Neoantigen Vaccine
    • Personalized Neo-Antigen Vaccine
  • Technology
    • HLA Typing
    • RNA Sequencing
    • Whole Genome Sequencing
  • Delivery Mechanism
    • Electroporation
    • Gene Gun
    • Liposomes
    • Virosomes
  • Neoantigen Type
    • Dendritic Cell
    • Nucleic Acid
    • Synthetic Long Peptide
    • Tumor Cell
  • Route of Administration
    • Intramuscular
    • Intravenous
    • Transdermal
  • Application
    • Brain Cancer
    • Gastrointestinal Cancer
    • Lung Cancer
    • Melanoma
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Neoantigen Cancer Vaccine Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Neoantigen Cancer Vaccine Market?

3. What are the technology trends and regulatory frameworks in the Neoantigen Cancer Vaccine Market?

4. What is the market share of the leading vendors in the Neoantigen Cancer Vaccine Market?

5. Which modes and strategic moves are suitable for entering the Neoantigen Cancer Vaccine Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Neoantigen Cancer Vaccine Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer globally
      • 5.1.1.2. Improvements in genomic sequencing and immunotherapy
      • 5.1.1.3. Inclination towards early diagnosis and treatment of cancer
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and complexity in manufacturing
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D to improve efficacy of neoantigen cancer vaccine
      • 5.1.3.2. Emerging development of combination therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects and ethical issues
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Neoantigen Cancer Vaccine Market, by Product

  • 6.1. Introduction
  • 6.2. Off-The Shell Neoantigen Vaccine
  • 6.3. Personalized Neo-Antigen Vaccine

7. Neoantigen Cancer Vaccine Market, by Technology

  • 7.1. Introduction
  • 7.2. HLA Typing
  • 7.3. RNA Sequencing
  • 7.4. Whole Genome Sequencing

8. Neoantigen Cancer Vaccine Market, by Delivery Mechanism

  • 8.1. Introduction
  • 8.2. Electroporation
  • 8.3. Gene Gun
  • 8.4. Liposomes
  • 8.5. Virosomes

9. Neoantigen Cancer Vaccine Market, by Neoantigen Type

  • 9.1. Introduction
  • 9.2. Dendritic Cell
  • 9.3. Nucleic Acid
  • 9.4. Synthetic Long Peptide
  • 9.5. Tumor Cell

10. Neoantigen Cancer Vaccine Market, by Route of Administration

  • 10.1. Introduction
  • 10.2. Intramuscular
  • 10.3. Intravenous
  • 10.4. Transdermal

11. Neoantigen Cancer Vaccine Market, by Application

  • 11.1. Introduction
  • 11.2. Brain Cancer
  • 11.3. Gastrointestinal Cancer
  • 11.4. Lung Cancer
  • 11.5. Melanoma

12. Americas Neoantigen Cancer Vaccine Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Neoantigen Cancer Vaccine Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Neoantigen Cancer Vaccine Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. FPNV Positioning Matrix
  • 15.2. Market Share Analysis, By Key Player
  • 15.3. Competitive Scenario Analysis, By Key Player

16. Competitive Portfolio

  • 16.1. Key Company Profiles
    • 16.1.1. "
    • 16.1.2. "Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
    • 16.1.3. Advaxis Inc.
    • 16.1.4. Agenus Inc.
    • 16.1.5. AstraZeneca plc
    • 16.1.6. Avidea Technologies
    • 16.1.7. BioLineRx
    • 16.1.8. BioNTech SE
    • 16.1.9. Brightpath Biotherapeutics Co., Ltd.
    • 16.1.10. CureVac N.V.
    • 16.1.11. Elicio Therapeutics Inc
    • 16.1.12. F. Hoffmann-La Roche Ltd.
    • 16.1.13. Genocea Biosciences Inc
    • 16.1.14. Gilead Sciences, Inc.
    • 16.1.15. Gritstone bio, Inc.
    • 16.1.16. Immunomic Therapeutics, Inc.
    • 16.1.17. IMV Inc
    • 16.1.18. ISA Pharmaceuticals BV
    • 16.1.19. Medigene AG
    • 16.1.20. Merck & Co., Inc.
    • 16.1.21. Neophore Limited
    • 16.1.22. Nouscom
    • 16.1.23. Nykode Therapeutics ASA
    • 16.1.24. OSE Immunotherapeutics
    • 16.1.25. Takis srl
  • 16.2. Key Product Portfolio

17. Appendix

  • 17.1. Discussion Guide
  • 17.2. License & Pricing